

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 30, 2026

KYNTRA BIO, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-36740
(Commission File Number)

77-0357827
(IRS Employer
Identification No.)

**350 Bay Street
Suite 100 #6009
San Francisco, California**
(Address of Principal Executive Offices)

94133
(Zip Code)

Registrant's Telephone Number, Including Area Code: 415 978-1200

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.01 par value	KYNB	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Director Appointment

Effective October 1, 2026, the Board of Directors (the “Board”) of the Kyntra Bio, Inc. (the “Company” or “Kyntra Bio”) appointed Andrew E. Singer, MBA as a Class III director of the Company. Mr. Singer was also appointed to the Audit Committee of the Board.

Kyntra Bio is delighted to welcome Mr. Singer to the Board. Mr. Singer’s biopharma related investment banking, strategic and transactions expertise will bring a valuable perspective to the Company as Kyntra Bio focuses on the development of novel therapies in oncology and rare disease.

Mr. Singer will hold office for the term expiring 2029. Mr. Singer will receive compensation as a non-employee director of the Company as approved by the Board under the Company’s Non-Employee Director Compensation Policy, as amended and approved by the Board on April 10, 2026.

Mr. Singer will enter into the Company’s standard Indemnity Agreement, effective October 1, 2026, a form of which is filed as Exhibit 10.15 with the Company’s Form 10-K for the year ended December 31, 2025, as filed with the SEC on March 16, 2026.

A copy of the Company’s press release announcing the appointment of Mr. Singer to the Board is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Director Resignation

Effective September 30, 2026, Maykin Ho, Ph.D. will resign from service on the Board of Kyntra Bio. Dr. Ho’s resignation as director is not the result of any disagreement with the Company or its management on any matter relating to the Company’s operations, policies, or practices.

Dr. Ho joined the Company’s Board in December 2018 and served in a number of capacities during her tenure with the Company, including as a member of the Audit Committee. Dr. Ho’s financial expertise was instrumental throughout her tenure, including as the Company achieved regulatory approval outside of the United States and commercially launched roxadustat in international markets, including the People’s Republic of China.

The Company is extremely grateful for the valuable guidance and direction Dr. Ho provided over the years and extends its best wishes for her future endeavors.

Change-in-Control and Severance Agreement of Thane Wettig

On September 30, 2026, the Company entered into a new Change in Control and Severance Agreement with our CEO, Thane Wettig, replacing the prior agreement that will expire on October 2, 2026. The new agreement has substantially the same terms and conditions as the prior agreement, including the severance and change-in-control benefits described in the Company’s Current Report on Form 8-K filed on July 25, 2023, which description is incorporated herein by reference. The new agreement has a three-year term ending October 2, 2029. There were no material changes to the compensation or benefits payable under the agreement.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release dated October 1, 2026.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

KYNTRA BIO, INC.

Date: September 30, 2026

By: /s/ John Alden

John Alden
General Counsel



Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of Directors

SAN FRANCISCO, October 1, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced the appointment of Andrew E. Singer, MBA to its Board of Directors as an independent director and member of the Audit Committee effective October 1, 2026. The Company also announced that Maykin Ho, Ph.D. has stepped down from the Board of Directors effective September 30, 2026 after nearly eight years of service.

“We are pleased to welcome Andy to the Board. His extensive experience across biotechnology finance, corporate development and public company operations will bring valuable perspective as Kyntra Bio continues to build momentum across its differentiated rare disease and oncology pipeline and execute on its strategic priorities,” said James A. Schoeneck, Chairman of the Board of Directors of Kyntra Bio. “On behalf of the Board and the management team, I also want to thank Maykin for her service and contributions to the company.”

“Kyntra Bio has taken substantial steps to strengthen its financial position and sharpen its focus on its exciting pipeline,” said Mr. Singer. “I look forward to working with the Board and management team to support the company as it advances its programs to create long-term value.”

Andrew E. Singer, MBA

Mr. Singer is a biotechnology finance and strategy executive with more than 25 years of experience spanning investment banking, corporate strategy, business development and public company leadership. He currently serves as Founder and CEO of Fika Bio Consulting, Inc., a strategic consulting firm. Previously, Mr. Singer served as Head of West Coast Biotechnology Investment Banking at Credit Suisse. Prior to Credit Suisse, Mr. Singer was a Managing Director in the Biotechnology Investment Banking Group at Wells Fargo, Executive Vice President and Chief Financial Officer of Epizyme, and spent over ten years at RBC Capital Markets in the Biotechnology Investment Banking Group. Over the course of his banking career, he advised biotechnology companies on capital formation, strategic transactions, and corporate development and participated in transactions valued in excess of \$50 billion. Mr. Singer previously served on the Board of Directors of Enlivex Therapeutics, Ltd. and the J.F. Kapnek Trust. He holds an MBA with distinction from Harvard Business School, and a BA from Yale University.

About Kyntra Bio

Kyntra Bio is a biopharmaceutical company focused on development of novel therapies in oncology and rare disease. Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in Europe, Japan, China, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate the development plan for the Phase 3 trial of roxadustat in anemia associated with lower-risk myelodysplastic syndromes (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase 2 development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit www.kyntrabio.com.

For Investor Inquiries:

David DeLucia, CFA
Senior Vice President and Chief Financial Officer
ir@kyntrabio.com
